Payment overview · 2025
General Payments
$196.44
10 reported records · 6 companies
Healthcare provider profile · identity verified
Stephanie Gill, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · NORWOOD, MA · NPI 1003933268
Verified facts
What the public records show
CMS Open Payments records show Stephanie Gill, NP received $196.44 in general payments during 2025 across 10 reported records.
Lundbeck LLC accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.45 | 24.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.74 | 20.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.90 | 19.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.41 | 18.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.99 | 9.2% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $16.95 | 8.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $196.44 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $47.45 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.90 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.41 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.41 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
72 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 660 | 182 |
| Omeprazole | Omeprazole | 393 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 333 | 103 |
| Lisinopril | Lisinopril | 301 | 88 |
| Oxycodone Hcl | Oxycodone Hcl | 269 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 77 |
| Simvastatin | Simvastatin | 241 | 64 |
| Losartan Potassium | Losartan Potassium | 239 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 48 |
| Metformin Hcl | Metformin Hcl | 178 | 49 |
| Lorazepam | Lorazepam | 174 | 36 |
| Gabapentin | Gabapentin | 166 | 42 |
| Alprazolam | Alprazolam | 143 | 19 |
| Tramadol Hcl | Tramadol Hcl | 134 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 20 |
| Furosemide | Furosemide | 113 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 32 |
| Morphine Sulfate Er | Morphine Sulfate | 111 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 111 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 30 |
| Allopurinol | Allopurinol | 108 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 15 |
| Famotidine | Famotidine | 96 | 23 |
| Atenolol | Atenolol | 85 | 25 |
| Diazepam | Diazepam | 84 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 22 |
| Pregabalin | Pregabalin | 78 | 15 |
| Ibuprofen | Ibuprofen | 75 | 21 |
| Eliquis | Apixaban | 72 | 15 |
| Clonazepam | Clonazepam | 71 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | 16 |
| Glipizide Er | Glipizide | 58 | 17 |
| Trazodone Hcl | Trazodone Hcl | 55 | 15 |
| Potassium Chloride | Potassium Chloride | 52 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 18 |
| Sertraline Hcl | Sertraline Hcl | 49 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 11 |
| Finasteride | Finasteride | 35 | 12 |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Carvedilol | Carvedilol | 28 | suppressed |
| Folic Acid | Folic Acid | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 25 | 20 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | 11 |
| Bumetanide | Bumetanide | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Celecoxib | Celecoxib | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Oxycontin | Oxycodone Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Oxazepam | Oxazepam | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Fondaparinux Sodium | Fondaparinux Sodium | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $196.44 · 10 records | Lundbeck LLC | ABRYSVO, COMIRNATY, ELIQUIS, MOUNJARO, NURTEC ODT, PREVNAR 20, QULIPTA, REXULTI, SYNTHROID, UBRELVY, Wegovy, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error